Article
Oncology
Emanuele Perrone, Riccardo Tudisco, Pia Clara Pafundi, Davide Guido, Alessandra Ciucci, Enrica Martinelli, Gian Franco Zannoni, Alessia Piermattei, Saveria Spadola, Giulia Ferrante, Claudia Marchetti, Giovanni Scambia, Anna Fagotti, Daniela Gallo
Summary: This study explored the relationship between hormone receptor status and BRCA1/2 mutation in high-grade serous ovarian carcinoma (HGSOC) patients. The results showed interesting differences in receptor expression patterns and their association with outcomes between BRCA-mutated and BRCA wild-type women. The findings suggest a potential role of estrogen-mediated pathways in BRCA1/2-associated HGSOC tumorigenesis, revealing a possible therapeutic potential for targeting this interaction.
Article
Cell Biology
Charlene Thiebaut, Virginie Vlaeminck-Guillem, Olivier Tredan, Coralie Poulard, Muriel Le Romancer
Summary: Steroid receptors play a crucial role in regulating cellular responses to steroids through both genomic and non-genomic signaling pathways. Research on non-genomic signaling in breast and prostate cancers has shown its clinical importance and potential for developing therapeutic strategies. Understanding the non-genomic pathways of ER, PR, AR, and GR may offer new perspectives for cancer treatment.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Article
Oncology
Hengqiang Zhao, Yiping Gong
Summary: Single estrogen receptor (ER)+ and progesterone receptor (PR)+ tumors account for about 10% of all breast cancers. The prognosis of these tumors varies based on HER2 status, with single ER+ and PR+ patients showing different survival outcomes in different HER2 subtypes. In HER2- subtype, single PR+ patients had poorer prognoses than single ER+ patients, while in HER2+ subtype, single ER+ and PR+ patients showed similar prognoses compared with ER-PR- patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jiahong Tan, Chunyan Song, Daoqi Wang, Yigang Hu, Dan Liu, Ding Ma, Qinglei Gao
Summary: High-grade serous ovarian cancer (HGSOC) with high expression of hormone receptors, including androgen receptor (AR), estrogen receptor alpha (ER), and progesterone receptor (PR), is associated with longer progression-free survival (PFS), overall survival (OS), and platinum-free interval (PFI). Correlation analysis shows significant positive correlations between hormone receptor expression and survival, indicating that AR, ER, and PR could serve as feasible prognostic biomarkers for HGSOC through immunohistochemical analysis. Co-expression of AR, ER, and PR has an improved predictive performance with an area under the curve (AUC) value of 0.945.
BIOSCIENCE REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Shaimaa Hamza, Ekaterina E. E. Garanina, Mohammad Alsaadi, Svetlana F. F. Khaiboullina, Gulcin Tezcan
Summary: NLRP3 may contribute to the growth and propagation of breast cancer, and the effects of ER-alpha, PR, and HER2 on NLRP3 activation in breast cancer are still unknown.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess, Fabrice Andre, Attila Tordai, Jaime A. Mejia, W. Fraser Symmans, Ana M. Gonzalez-Angulo, Bryan Hennessy, Marjorie Green, Massimo Cristofanilli, Gabriel N. Hortobagyi, Lajos Pusztai
Summary: This study compared the response to neoadjuvant chemotherapy and survival between patients with triple-negative breast cancer (TNBC) and non-TNBC. The results showed that TNBC patients had higher pathologic complete response rates but lower 3-year progression-free survival rates and 3-year overall survival rates. TNBC was associated with increased risk for visceral metastases, lower risk for bone recurrence, and shorter postrecurrence survival. Patients with TNBC had worse survival if they had residual disease after neoadjuvant chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Naoko Honma, Yoko Matsuda, Tetuo Mikami
Summary: TNBC lacks an effective treatment target and is usually associated with a poor clinical outcome due to hormone unresponsiveness. Besides ER-alpha, other sex steroid receptors like AR, ER-beta, and GPER are frequently expressed in TNBC, highlighting the importance of understanding their biological and clinical significance in TNBC. A comprehensive viewpoint on the role of sex steroid hormones in TNBC is crucial for correctly understanding the association between the carcinogenic mechanism or pathobiology of TNBC and sex steroid hormones.
Review
Oncology
Darcie D. Seachrist, Lindsey J. Anstine, Ruth A. Keri
Summary: The review discusses the role of FOXA1 in regulating gene activity, cell biology, and the response of breast cancers to hormone therapies. It also highlights the potential for future studies to explore the roles of FOXA1 independent of its regulation of nuclear receptors.
Article
Cell Biology
Shabnam Massah, Jane Foo, Na Li, Sarah Truong, Mannan Nouri, Lishi Xie, Gail S. Prins, Ralph Buttyan
Summary: ER alpha interacts with Gli3 in breast cancer cells, leading to Gli3 stabilization and increased expression of Gli-target genes with estradiol treatment. Additionally, Gli3 is found to be essential for breast cancer cell growth, suggesting that ER alpha-Gli interaction and Gli3 could be novel targets for controlling breast cancer growth effectively.
MOLECULAR AND CELLULAR ENDOCRINOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Stuti Roy, Suryendu Saha, Debanil Dhar, Puja Chakraborty, Kumar Singha Roy, Chitranjan Mukherjee, Arnab Gupta, Samir Bhattacharyya, Anup Roy, Sanghamitra Sengupta, Susanta Roychoudhury, Somsubhra Nath
Summary: This study reveals the role of CUEDC2 in breast cancer, especially in endocrine resistance and mitotic progression. Upregulation of CUEDC2 renders ERα+ve tumors behave similarly to HR-ve tumors with an increase in aneuploidy. Furthermore, CUEDC2 is identified as a potential prognostic marker and therapeutic target in breast cancer management.
CANCER GENE THERAPY
(2022)
Review
Endocrinology & Metabolism
Xue-Ling Xu, Zheng-Yuan Huang, Kun Yu, Jun Li, Xiang-Wei Fu, Shou-Long Deng
Summary: This review focuses on the role of ER alpha and ER beta in polycystic ovary syndrome (PCOS), ovarian cancer, and premature ovarian failure (POF), as well as the major challenges of existing therapies. It provides a reference for the treatment of estrogen target tissue ovarian diseases.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Multidisciplinary Sciences
Johanna M. Schafer, Tong Xiao, Hyunwoo Kwon, Katharine Collier, Yuzhou Chang, Hany Abdel-Hafiz, Chelsea Bolyard, Dongjun Chung, Yuanquan Yang, Debasish Sundi, Qin Ma, Dan Theodorescu, Xue Li, Zihai Li
Summary: This article explains the reasons behind higher incidence and mortality rates for males in non-reproductive system cancers, focusing on the role of sex chromosomes and sex hormones in driving differential adaptive immunity. The article highlights the involvement of cell-intrinsic androgen receptors in CD8(+) T cell dysfunction or exhaustion in the tumor microenvironment, and summarizes ongoing clinical efforts to investigate the impact of androgen blockade on cancer immunotherapy. It emphasizes the importance of a comprehensive research approach to understanding sex dimorphisms in cancer and advocating for considering sex as a crucial factor in guiding treatment decisions in the future.
Article
Endocrinology & Metabolism
Amani A. Mahbub, Akhmed Aslam, Mohamed E. Elzubier, Mohamed El-Boshy, Abdelghany H. Abdelghany, Jawwad Ahmad, Shakir Idris, Riyad Almaimani, Aiman Alsaegh, Mahmoud Zaki El-Readi, Mohammed A. Baghdadi, Bassem Refaat
Summary: The study found that the individual use of E2 and P4 can inhibit the development of colorectal cancer, showing good anti-tumor effects in male mice and cell experiments. The combination of the two shows a stronger anti-cancer effect.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Dermatology
Amirun Rahmat, Iris De Nie, Chantal M. Wiepjes, Martin Den Heijer, Thomas Rustemeyer, Christel J. M. De Blok, Koen M. A. Dreijerink
Summary: This study aimed to determine the incidence of skin cancer in transgender individuals receiving gender-affirming hormone treatment (GAHT). The results showed that GAHT did not appear to affect skin cancer incidence in this large cohort of transgender individuals.
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Article
Oncology
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Donatella Gambini, Concetta Blundo, Letterio Runza, Stefano Ferrero, Elena Guerini-Rocco, Nicola Fusco
Summary: The loss of PTEN is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer patients. Patients with PTEN-low tumors showed significantly enriched hormone receptor negativity and HER2 negativity compared to those with PTEN-retained tumors. The combined analysis of PTEN, HER2, and hormone receptor status provides relevant information for a more precise risk assessment of patients with breast cancer.